GAO Report on Drug Safety Oversight

This post was written by Paul Sheives.

A recent GAO report points to improvement in FDA’s postmarket drug safety oversight, but the agency expresses concern over continued gaps in particular areas. The GAO recommended that FDA develop a plan and timeline for transferring additional regulatory authorities from the Office of New Drugs to the Office of Surveillance and Epidemiology. FDA comments regarding the report were generally supportive, but the agency is hesitant to commit to any timelines.

Trackbacks (0) Links to blogs that reference this article Trackback URL
http://www.healthindustrywashingtonwatch.com/admin/trackback/173782
Comments (0) Read through and enter the discussion with the form at the end
Post A Comment / Question Use this form to add a comment to this entry.







Remember personal info?